PHAXIAM Therapeutics SA

PHAXIAM Therapeutics SA operates as a biopharmaceutical company. It engages in the development of treatments for resistant bacterial infections. The firm develops antibacterial treatments based on the use of bacteriophage viruses, or phages, to combat bacterial infections in humans, particularly those resistant to antibiotics. The company was founded in 2004 and is headquartered in Lyon, France.

PRESS RELEASE PHAXIAM Therapeutics announces the completion of its reverse share split Lyon (France) and Cambridge (MA, US) , September 18 th , 2023 - PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM ) ( the " Company") , announces the completion today of the reverse share split of the shares composing the Company's share capital, as decided by the Executive Director on July 27 th , 2023 , following sub-delegation granted by the Board of Directors on June  23 rd , 2023, made in accordance with the twenty-third extraordinary resolution of the General Shareholders ' Meeting of June 23 rd , 2023 . The reverse share split involved the exchange of ten (10) existing shares with a par value of ten euro cents (€0.10) (the "Existing Shares") for one (1) new share with a par value of one euro (€1) (a "New Share").

PHAXIAM Therapeutics announces the completion of its reverse share split

P HAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences

PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences

PHAXIAM Therapeutics (NASDAQ: PHXM ) stock is taking off on Thursday despite a lack of news from the biopharmaceutical company. There haven't been any press releases or filings with the Securities and Exchange Commission (SEC) that explain why PHXM stock is up today.

News for PHAXIAM Therapeutics SA Stock (PHXM)